Access to anti-retroviral drugs, male in Eswatini

Eswatini: Access to anti-retroviral drugs, male was 84.0% in 2024. ◆ Volatile

Latest (2024)
84.0%
Change on year
up 5.0%
World rank
36th
of 141 countries
All-time high
84.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Eswatini, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 1 %2003: 2 %2004: 3 %2005: 6 %2006: 10 %2007: 12 %2008: 15 %2009: 18 %2010: 25 %2011: 28 %2012: 32 %2013: 37 %2014: 44 %2015: 56 %2016: 63 %2017: 63 %2018: 65 %2019: 71 %2020: 77 %2021: 75 %2022: 78 %2023: 80 %2024: 84 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Eswatini stood at 84.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 5.0% on the previous year and up 90.9% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Eswatini peaked at 84.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Eswatini 36th out of 141 countries with data for 2024, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Eswatini, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Eswatini, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 1.0%
2003 2.0% +100.0%
2004 3.0% +50.0%
2005 6.0% +100.0%
2006 10.0% +66.7%
2007 12.0% +20.0%
2008 15.0% +25.0%
2009 18.0% +20.0%
2010 25.0% +38.9%
2011 28.0% +12.0%
2012 32.0% +14.3%
2013 37.0% +15.6%
2014 44.0% +18.9%
2015 56.0% +27.3%
2016 63.0% +12.5%
2017 63.0% +0.0%
2018 65.0% +3.2%
2019 71.0% +9.2%
2020 77.0% +8.5%
2021 75.0% -2.6%
2022 78.0% +4.0%
2023 80.0% +2.6%
2024 84.0% +5.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.7% 0.0% 18.0% 10
2010s 48.4% 25.0% 71.0% 10
2020s 78.8% 75.0% 84.0% 5

Countries ranked near Eswatini

  1. 34 Italy 85.0% compare
  2. 34 New Zealand 85.0% compare
  3. 36 Croatia 84.0% compare
  4. 36 Kenya 84.0% compare
  5. 36 Nigeria 84.0% compare

See the full ranking of 160 places →

More gender data for Eswatini

All data for Eswatini →

Frequently asked questions

What is access to anti-retroviral drugs, male in Eswatini?
Access to anti-retroviral drugs, male in Eswatini was 84.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Eswatini?
The highest recorded value was 84.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Eswatini?
The lowest recorded value was 0.0% in 2000.
How does Eswatini rank for access to anti-retroviral drugs, male?
Eswatini ranks 36th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Eswatini?
Over the last ten years it is up 90.9%. The long-run trend across the full record is volatile.
Where does this Eswatini data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Eswatini. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/eswatini/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/eswatini/">Access to anti-retroviral drugs, male in Eswatini</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.